Results 51 to 60 of about 690,202 (278)

Sample size calculation for estimating infinite population proportion.

open access: yes, 2023
Sample size calculation for estimating infinite population proportion.
Saw Simon (16747422)   +4 more
core   +1 more source

Clinical and Biological Features of Response in Resistant Neuroblastoma to 131I‐Metaiodobenzylguanidine Radiotherapy in the Anti‐GD2 Immunotherapy Era

open access: yesPediatric Blood &Cancer, EarlyView.
ABSTRACT Background 131I‐metaiodobenzylguanidine (131I‐MIBG) radiotherapy is a key treatment for relapsed and refractory (R/R) neuroblastoma (NB). Patients with R/R disease treated in the modern era are increasingly exposed to anti‐GD2 immunotherapy, which exerts selective pressure and may modify both tumor cell state and microenvironment.
Benjamin J. Lerman   +7 more
wiley   +1 more source

Sample Size Calculation for Controlling False Discovery Proportion

open access: yesJournal of Probability and Statistics, 2012
The false discovery proportion (FDP), the proportion of incorrect rejections among all rejections, is a direct measure of abundance of false positive findings in multiple testing.
Shulian Shang   +3 more
doaj   +1 more source

How to calculate sample size in animal and human studies

open access: yesFrontiers in Medicine, 2023
One of the most important statistical analyses when designing animal and human studies is the calculation of the required sample size. In this review, we define central terms in the context of sample size determination, including mean, standard deviation,
Xinlian Zhang   +2 more
doaj   +1 more source

Venous Thromboembolism in Pediatric Bone Sarcoma Patients: A 10‐Year, Single‐Institution Experience Encompassing the COVID‐19 Pandemic

open access: yesPediatric Blood &Cancer, EarlyView.
ABSTRACT Background Osteosarcoma (OS) and Ewing sarcoma (EWS) are the most common primary bone cancers in children, but acute thrombosis is poorly characterized in this population. Our study evaluated the rates of venous thromboembolism (VTE) and associated risk factors in pediatric patients with bone sarcomas treated over a 10‐year period encompassing
Sarah Kappa   +8 more
wiley   +1 more source

Flowchart of the proposed algorithm for sample size calculation.

open access: yes, 2023
Flowchart of the proposed algorithm for sample size calculation.
Yuxuan Chen (1511149)   +2 more
core   +1 more source

Serological Benefit of SARS‐CoV‐2 Vaccination Relative to Infection in Children With Acute Lymphoblastic Leukemia

open access: yesPediatric Blood &Cancer, EarlyView.
ABSTRACT Background Children with acute lymphoblastic leukemia (ALL) are at risk of severe outcomes from SARS‐CoV‐2 (SCV2). In the post‐pandemic context, where most children have been infected with SCV2, there are limited data on whether vaccination remains beneficial in children with ALL.
Janna R. Shapiro   +11 more
wiley   +1 more source

Sample size calculation based on different possible misclassification rates.

open access: yes, 2023
Sample size calculation based on different possible misclassification rates.
Steffen Geis (354936)   +6 more
core   +1 more source

Sample Size Determination for Food Sampling

open access: yesJournal of Food Protection, 2023
Industry and public health agencies sample and test food products for various purposes related to food safety and quality. Methods of sample selection and sample size determination are important in designing an optimal sampling plan.
Shizhen S. Wang   +3 more
doaj   +1 more source

Deep Sequencing of FLT3‐ITD Enables Response Evaluation and Post‐Treatment Monitoring in Childhood AML: An Exploratory Study

open access: yesPediatric Blood &Cancer, EarlyView.
ABSTRACT Background An internal tandem duplication in the gene encoding Fms‐like tyrosine kinase 3 (FLT3‐ITD) is associated with high relapse risk and poor prognosis in acute myeloid leukemia (AML) and plays a crucial role in treatment decisions. Measurable residual disease (MRD) analysis of FLT3‐ITD during and after treatment has shown prognostic ...
Sofie Johansson Alm   +11 more
wiley   +1 more source

Home - About - Disclaimer - Privacy